Aquino-Andrade A, Ribas-Aparicio RM, Filio-Rodríguez G, Coria-Jiménez R, Rolón-Montes de Oca AL, Aparicio-Ozores G

Language: Spanish
References: 24
Page: 175-182
PDF size: 90.73 Kb.

ABSTRACT

Pseudomonas aeruginosa has several mechanisms of resistance to the action of antimicrobials: enzymatic inactivation of antibiotics, changes in the target site and the membrane permeability, and the expulsion of antibiotics that are able to enter the cell. This latter mechanism is via activation of efflux pumps, also known as removal systems. The aim of this study was to develop a phenotypic method that uses antibiotic as reporters and an inhibitor of removal systems to detect efflux pumps in multidrug-resistant strains of P. aeruginosa from clinical origin. We determined the minimal inhibitory concentration (MIC) to 16 antibiotics at 21 strains tested. We performed the detection of extended spectrum β-lactamases (ESBL) and metallo β-lactamases (MBL). For detection of efflux pumps of Mex type, different antibiotics were used as reporters: carbenicillin for MexAB-OprM, erythromycin for MexCD-OprJ, norfloxacin for MexEF-OPRN, and gentamicin for MexXY. The MIC for each antibiotic was determined in absence and presence of the phenyl-arginine-β-naftilamine (FAbN), which acted as an inhibitor for efflux pumps. The strains tested were resistant to at least three antibiotics from different families, which showed the phenomenon of multidrug resistance. ESBL or MBL production was not detected in any of the strains tested. All strains reduced the CIM at least for one of the substrates in the presence of FAβN. Removal systems detected that were associated with resistance, showed the following frequencies: MexCD-OPRN and MexCD-OprJ with 86%, MexAB-OprM with 52%, and MexXY with 43%.

REFERENCES

1. Kiewitz C, Tümbler B. Sequence diversity of Pseudomonas aeruginosa: impact on population structure and genome evolution. J Bacteriol. 2000; 182: 3125-35.

2. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005; 25: 1353-64.

3. Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect. 2006; 36: 78-91.

4. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007; 13: 560-78.

5. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanism. Clin Microbiol Rev. 2009; 22: 582-610.

6. Yoshihara E, Eda S. Diversity in the oligomeric channel structure of the multidrug efflux pumps in Pseudomonas aeruginosa. Microbiol Immunol. 2007; 51: 47-52.

7. Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006; 19: 382-402.

8. CLSI/NCCLS. Performance standards for antimicrobial susceptibility testing. Supplement M100-S15. Clinical and Laboratory Standards Institute. Wayne, Philadelphia, USA. 2005.

9. CLSI/NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 6th edition. M07-A6. Clinical and Laboratory Standards Institute. Wayne, Philadelphia, USA. 2005.

10. Mesaros N, Glupczynski Y, Avrain L, Caceres NE, Tulkens PM, Van Bambeke F. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother. 2007; 59: 378-86.

11. Henrichfreise B, Wiegan I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother. 2007; 52: 4062-70.

12. Giske CG, Buarø L, Sundsfjord A, Wretlind B. Alterations of porins pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa. Microb Drug Resistance. 2008; 14: 23-30.

13. Pournaras S, Ikonomidis A, Markogiannakis A, Spanakis N, Maniatis AN, Tsakris A. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems. J Med Microbiol. 2007; 56: 66-70.

14. Lee YC, Ahn BJ, Jin JS, Kim JU, Lee SH, Song DY, et al. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin in Daegu Korea. J Clin Microbiol. 2007; 45: 358-63.

15. Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J. Comparison of type III secretion system virulence among fluoroquinolone susceptible and resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2008; 14: 330-6.

16. Pasquali F, Manfreda G. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Vet Microbiol. 2007; 119: 304-10.

17. Taneja N, Rao P, Arora J, Dogra A. Occurrence of ESBL & Amp-C b-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res. 2008; 127: 85-8.

18. Empel J, Filczak K, Mrówka A, Htyniewicz W, Livermore DM, Gniadkowski M. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum b-lactamase in Warsaw Poland: further evidence for an international clonal complex. J Clin Microbiol. 2007; 45: 2829-34.

19. Doi Y, Oliveira DJ, Adams J, Paterson DL. Coproduction of novel 16S rRNA methylase RmtD and metallo-b-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother. 2007; 51: 852-6.

20. Jo JTH, Brinkman FSL, Hancock REW. Aminoglycoside efflux in Pseudomonas aeruginosa: Involvement of novel outer membrane proteins. Antimicrob Agents Chemother. 2003; 47: 1101-11.

21. Hirakata Y, Kondo A, Hoshino K, Yano H, Arai K, Hirotani A, Kunishima H, Yamamoto, Hatta M, Kitagawa M, Kohno S, Kaku M. Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2009; 34: 343-6.

22. Tohidpour A, Najar-Peerayeh S, Mehrabadi JF, Rezaei-Yazdi H. Determination of the efflux pump-mediated resistance prevalence in Pseudomonas aeruginosa, using an efflux pump inhibitor. Curr Microbiol. 2009; 59: 352-5.

23. Jeannot K, Sobel ML, Garch FE, Poole K, Plésiat P. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug ribosome interaction. J Bacteriol. 2005; 187: 5341-6.

24. Masuda N, Sakagawa E, Ohya S, Gotoh H, Tsujimoto H, Nishino T. Contribution of MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000; 44: 2242-6.